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Abstract
Background—The rabies virus causes a fatal encephalitis and can be transmitted through organ 
transplantation. In 2013, a man developed rabies 18 months after receiving a kidney from a donor 
with rabies, who was not known to have been infected when the organs were procured. Three 
additional persons who received organs from the same donor (liver, kidney, heart), all of whom 
were not vaccinated for rabies before transplantation, received rabies post-exposure prophylaxis 
(PEP) with rabies immune globulin and 5 doses of rabies vaccine as soon as the diagnosis of 
rabies was made in the donor (18 months after their transplant surgeries). We describe their 
clinical management.
Methods—As the 3 recipients were all on immunosuppressive medications, post-vaccination 
serologic testing was performed using the rapid fluorescent focus inhibition test to measure rabies 
virus neutralizing antibodies (RVNAs). An acceptable antibody response to administration of 
rabies vaccine was defined as detection of RVNAs at a concentration ≥0.1 IU/mL from a serum 
specimen collected ≥7 days after the fifth vaccine dose.
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Results—All 3 recipients demonstrated an acceptable antibody response despite their 
immunosuppressed states. More than 36 months have passed since their transplant surgeries, and 
all 3 recipients have no evidence of rabies.
Conclusions—The survival of 3 previously unvaccinated recipients of solid organs from a 
donor with rabies is unexpected. Although the precise factors that led to their survival remain 
unclear, our data suggest that PEP can possibly enhance transplant safety in settings in which 
donors are retrospectively diagnosed with rabies.
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Rabies is a fatal encephalitis caused by the rabies virus. An estimated 55,000 humans die 
each year from rabies, and the majority of cases are related to bites from rabid dogs (1). 
Rabies can be prevented after conventional exposures, such as animal bites, through use of 
post-exposure prophylaxis (PEP), which for previously unvaccinated immunocompetent 
persons consists of rabies immune globulin (RIG) and 4 doses of rabies vaccine (2, 3).
The humoral response stimulated after administration of rabies vaccine involves production 
of rabies virus neutralizing antibodies (RVNAs) that can be measured with the rapid 
fluorescent focus inhibition test (RFFIT); administration of RIG provides an immediate 
supply of RVNAs while the host mounts this humoral response. According to the Advisory 
Committee on Immunization Practices (ACIP), an acceptable antibody response to 
administration of rabies vaccine can be documented if the host’s serum completely 
neutralizes challenge rabies virus at a serum dilution of 1:5; this corresponds to an 
approximate RVNA concentration of 0.1 IU/mL (2, 3). RVNA titers do not correlate with 
protection against rabies, and post-vaccination serologic testing is not routinely performed 
for immunocompetent persons because the majority will have an acceptable antibody 
response (2, 3). In contrast, immunosuppressed persons often have diminished antibody 
responses to rabies vaccines, although the precise factors associated with this suboptimal 
response are not well defined (2–7). ACIP therefore recommends that previously 
unvaccinated immunosuppressed persons receive RIG and 5 doses of vaccine, as well as 
postvaccination serologic testing to confirm that an acceptable antibody response has 
occurred (2).
While most rabies cases are associated with a history of direct exposure to rabid animals, 
rabies virus transmission can also occur through transplantation of tissues or organs that 
have been procured from infected human donors (8). For example, in 2004 and 2005, 2 
separate outbreaks of rabies occurred among persons who had received solid organs 
procured from donors not known to have rabies at the time of transplantation (9, 10). During 
both events, all recipients who had not received pre-transplant rabies vaccination developed 
rabies symptoms within 6 weeks of transplantation and subsequently died; this included 
recipients who were given PEP after the retrospective diagnosis of rabies was made in the 
donor. Observations from these outbreaks suggest a high infectivity rate among recipients of 
organs that have been procured from donors with rabies and raise questions about the 
effectiveness of PEP in this setting (8, 9).
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In 2013, we reported a third rabies virus transmission event through solid organ 
transplantation (11). In contrast to the 2 prior solid organ-associated outbreaks, out of a total 
of 4 previously unvaccinated solid organ recipients, only 1 (recipient of left kidney) 
developed rabies after an unusually long incubation period of 17 months. The 3 remaining 
recipients (liver, right kidney, heart) received PEP (with RIG and 5 doses of vaccine 
administered on PEP Days 0, 3, 7, 14, and 28) as soon as the diagnosis of rabies was made 
in the donor. Despite starting PEP 18 months after their transplant procedures, these 3 
recipients have, to date, not developed rabies (2, 3). This article describes the clinical 
management of these 3 recipients after the organ donor was retrospectively diagnosed with 
rabies, with a focus on the challenges of managing PEP for immunosuppressed persons.
Methods
The details of the public health investigation have been previously published (11, 12). As 
the 3 surviving recipients were all on immunosuppressive medications, post-vaccination 
serologic testing was performed using RFFIT on serial serum specimens (11, 13–15). The 
lower limit of detection for RVNAs by RFFIT was 0.04 IU/mL. A recipient was considered 
to have had an acceptable antibody response to administration of rabies vaccine if RVNAs 
were detected from serum at a concentration ≥0.1 IU/mL at least 7 days after the fifth 
vaccine dose had been administered. We also evaluated a baseline serum specimen collected 
prior to the administration of PEP, to verify if there had been any previous exposure to 
rabies virus antigens. The baseline serum specimen was tested for RVNAs (using RFFIT) 




The liver recipient was a 42-year-old man when he received his liver transplant for end-
stage liver disease from Budd–Chiari syndrome; he had not been vaccinated for rabies 
before the time of transplantation. Immediately prior to receiving the organ, the patient was 
critically ill with a model for end-stage liver disease score of 40. The patient’s transplant 
surgery was uneventful, as was his immediate post-transplant course, aside from renal 
failure; he was discharged home on post-transplant day 11.
The patient’s induction immunosuppressive regimen consisted of methylprednisolone (1 
intravenous [IV] dose of 1 g) and alemtuzumab (1 IV dose of 30 mg). His initial 
maintenance immunosuppressive regimen consisted of methylprednisolone tapered over the 
first 3 postoperative months and tacrolimus with initial serum trough level goals of 4–8 
ng/mL. During post-transplant month 8, the patient developed herpes zoster of the lower 
extremity, which was treated successfully with acyclovir; no adjustments were made to his 
immunosuppressive regimen. Other post-transplant complications included chronic renal 
insufficiency, diabetes controlled with oral hypoglycemic agents, and hypertension. He has 
no episodes of rejection of his transplanted liver.
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PEP consisted of RIG and 5 doses of purified chick embryo cell rabies vaccine (11). Serum 
collected 14 days after the fifth vaccine dose (PEP Day 42) demonstrated an acceptable 
antibody response to rabies vaccine; as of post-transplant month 28/PEP Day 280, RVNAs 
were still detectable at a concentration ≥0.1 IU/mL (Table 1, Fig. 1). The patient remains on 
maintenance immunosuppression with tacrolimus and has no clinical evidence of rabies.
Right kidney recipient
The right kidney recipient was a 41-year-old man with a history of hyperparathyroidism and 
Barrett’s esophagus when he received his renal transplant for hypertensive nephropathy; he 
had not been vaccinated for rabies before the time of transplantation. The patient’s 
transplant surgery was uneventful, as was his immediate post-transplant course aside from 
hypertension; he was discharged home on post-transplant day 3.
The patient’s induction immunosuppressive regimen consisted of methylprednisolone (rapid 
taper over 3 days starting with an IV dose of 500 mg) and alemtuzumab (1 IV dose of 30 
mg). His initial maintenance immunosuppressive regimen consisted of tacrolimus and 
mycophenolic acid with serum trough level goals of 8–12 ng/mL and 2–3 µg/mL, 
respectively. During post-transplant month 3, he developed BK virus-associated 
nephropathy and BK viremia, prompting reductions in tacrolimus and mycophenolic acid 
doses to maintain serum trough level goals of 6–8 ng/mL and 1.5–2.5 µg/mL, respectively. 
A kidney biopsy obtained during post-transplant month 12 showed resolution of BK virus-
associated nephropathy. He has not had any episodes of rejection of his transplanted kidney.
PEP consisted of RIG and a human diploid cell rabies vaccine for the first vaccine dose, and 
purified chick embryo cell rabies vaccine for the subsequent 4 vaccine doses (11). Serum 
collected 11 days after the fifth vaccine dose (PEP Day 39) demonstrated an acceptable 
antibody response to rabies vaccine; as of post-transplant month 28/PEP Day 279, RVNAs 
were still detectable at a concentration ≥0.1 IU/mL.
Several tests to measure immune function were performed during and after the course of 
PEP. T-cell analysis by flow cytometry at baseline (post-transplant month 18/PEP Day 0) 
revealed an absolute CD3 cell count of 189/mm3 (normal range 629–2465/mm3), absolute 
CD8 cell count of 46/mm3 (normal range 93–1025/mm3), and absolute CD4 cell count of 
133/mm3 (normal range: 340–1568/mm3). Quantitative immunoglobulins (Igs) measured at 
the same time (post-transplant month 18/PEP Day 0) were as follows: IgG 748 mg/dL 
(normal range 700–1600 mg/dL), IgA 105 mg/dL (normal range 70–400 mg/dL), and IgM 
52 mg/dL (normal range 40–230 mg/dL). Flow cytometry analysis on post-transplant month 
21/PEP Day 68 revealed an absolute CD3 cell count of 205/mm3, absolute CD8 cell count of 
68/mm3, and absolute CD4 cell count of 125/mm3. During post-transplant month 28/PEP 
Day 279, quantitative Ig measurement revealed the following: IgG 587 mg/dL, IgA 90 
mg/dL, and IgM 36 mg/dL. The patient remains on maintenance immunosuppression with 
tacrolimus and mycophenolic acid and has no clinical evidence of rabies.
Heart recipient
The heart recipient was a 54-year-old man with a history of diabetes mellitus type II and 
hypertension when he received his heart transplant for idiopathic dilated cardiomyopathy; he 
Vora et al. Page 4













had not been vaccinated for rabies before the time of transplantation. Immediately prior to 
receiving the organ, the patient was critically ill with methicillin-sensitive Staphylococcus 
aureus sepsis complicated by acute renal failure and recurrent ventricular tachycardia. The 
patient’s transplant surgery was uneventful, as was his immediate post-transplant course 
apart from renal failure; he was discharged home on post-transplant day 11.
The patient’s induction immunosuppressive regimen consisted of methylprednisolone (1 IV 
dose of 500 mg) and basilixmab (1 IV dose of 20 mg). He received an additional 1 g of 
methylprednisolone over the first 2 days postoperatively. His initial maintenance 
immunosuppressive regimen consisted of tacrolimus with initial serum trough level goals of 
10–14 ng/mL, prednisone (50 mg daily) tapered over the first 45 postoperative days to 15 
mg daily, and mycophenolate mofetil (1 g twice daily). During post-transplant month 2, he 
underwent a heart biopsy that showed grade 1A rejection; no adjustments were made to his 
immunosuppressive regimen. A heart biopsy during posttransplant month 3 showed grade 
1B rejection; no adjustments were made to his immunosuppressive regimen. A heart biopsy 
during post-transplant month 4 showed resolution of rejection and his tacrolimus dose was 
titrated to target serum trough level goals of 10–12 ng/mL and his prednisone dose was 
subsequently weaned to 12.5 mg daily. The patient continued to have episodes of grade 1A 
rejection during post-transplant months 12 and 15, but no adjustments were made to his 
immunosuppressive regimen.
PEP consisted of RIG and a purified chick embryo cell rabies vaccine for the first 4 vaccine 
doses, and a human diploid cell rabies vaccine for the fifth vaccine dose (11). Serum 
collected 21 days after the fifth vaccine dose (PEP Day 49) demonstrated an acceptable 
antibody response to rabies vaccine; as of post-transplant month 36/PEP Day 533, RVNAs 
were not detectable. The patient remains on maintenance immunosuppression with 
tacrolimus and sirolimus, and has no clinical evidence of rabies.
Discussion
Three clusters of human rabies associated with solid organ transplantation have been 
reported globally, all of which occurred in countries with very low burdens of human rabies 
(9–11). In other parts of the world, including areas where canine rabies is endemic and 
human rabies is more common, organ transplantation is an increasingly utilized medical 
intervention (16). These circumstances underscore the need to investigate means of 
preventing transplant-associated rabies through primary prevention strategies, such as 
improving recognition of rabies among potential donors, and through secondary prevention 
strategies, such as PEP.
The survival of the 3 recipients described here, none of whom had been vaccinated for 
rabies at the time of their transplant surgeries, is unprecedented. Unfortunately, the precise 
factors that led to their survival remain unclear. Eighteen months had already passed when it 
was discovered that these 3 recipients had received organs from a donor with rabies and all 3 
were asymptomatic at the time. One explanation for this is that these 3 recipients had 
received organs without any burden of rabies virus and were therefore not at risk for rabies, 
given that the typical incubation period of the rabies virus is <1 year. However, the long 
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incubation period of 17 months experienced by the 1 recipient who did develop rabies is 
evidence against this hypothesis (11). Another possibility is that these 3 recipients were 
exposed to a subinfectious dose of rabies virus that had been cleared prior to PEP 
administration. Similar incidents have been reported among persons who have been bitten 
by rabid animals, but who do not develop rabies despite not receiving PEP (17, 18). A third 
possibility, and most concerning, is that these 3 recipients were within the incubation period 
of the rabies virus and would have experienced clinical disease had they not received PEP; 
therefore, we administered PEP according to a schedule recommended by ACIP. It is 
notable that the donor was infected with the raccoon rabies virus variant, and an additional 
question that remains unresolved is whether this might explain the different outcome of 
these 3 recipients, compared with the unvaccinated recipients in the 2 prior transplant-
associated rabies outbreaks in 2004 and 2005 (9, 10). Raccoons are the most frequently 
reported rabid animal in the United States, yet only 3 cases of human infection with the 
raccoon rabies virus variant have ever been reported (11). While we know that infection 
with the raccoon rabies virus variant in humans is fatal, it is possible that this rabies virus 
variant has a different natural history in the human host (such as a longer incubation period) 
compared with other rabies virus variants (such as those from bats).
We performed post-vaccination serologic testing for the 3 recipients, given their 
immunosuppressed status, as recommended by ACIP. ACIP does not specify whether a 
single serum sample or serial samples should be evaluated, though some authors have 
argued that a single sample is sufficient, if target antibody levels are demonstrated (19). This 
approach for management of PEP for immunosuppressed persons is often reasonable for 
conventional rabies virus exposures, such as animal bites, in which there is a discrete, finite 
exposure. However, we considered the 3 recipients as potentially being at continuous risk 
for rabies virus exposures, given the possibility that their transplanted organs still harbored 
rabies virus. Furthermore, the sites of their exposure (their transplanted organs) could not be 
washed, as is typically done for bite wounds (an action that reduces the risk of rabies even in 
the absence of PEP), and because their transplanted organs could not be directly infiltrated 
with RIG (2, 20, 21). We therefore collected serial serum samples from all 3 recipients as 
part of their post-vaccination serologic testing.
The criteria we used to establish whether an acceptable antibody response had occurred was 
consistent with that recommended by ACIP: complete neutralization of challenge rabies 
virus at a serum dilution of 1:5 using RFFIT, which roughly corresponds to an RVNA 
concentration of 0.1 IU/mL. In contrast, the World Health Organization (WHO) 
recommends that a concentration of 0.5 IU/mL be used as a cutoff (22). Ultimately, these 
are arbitrary standards and having an RVNA concentration above these levels does not 
confer “protection” against rabies (5, 19). It is estimated that as many as 36,000 persons 
receive PEP in the United States each year, and although PEP is not always properly 
administered and despite using a lower RVNA cutoff for an acceptable antibody response 
than WHO, there have been no reports in the United States of failures of PEP with the 
currently licensed cell-culture rabies vaccines (2, 23). The difference between the ACIP and 
WHO criteria are important to consider, however, because the heart recipient never 
developed a concentration of RVNAs ≥0.5 IU/mL, and the right kidney recipient did not 
develop a concentration of RVNAs ≥0.5 IU/mL until the last serum draw on PEP Day 279. 
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Few data are available to guide management of PEP for immunosuppressed persons when 
neither of these RVNA cutoffs is reached, and greatly divergent strategies have been 
proposed, including repeat administration of the entire PEP series and doubling of the 
vaccine dose (4, 24). Until more data are available to help standardize management of PEP 
for immunosuppressed persons, each case will have to be managed individually, often in 
consultation with appropriate public health officials. Adverse events can occur as a result of 
receiving rabies vaccine, and therefore the benefits and risks of administering extra doses of 
vaccine beyond the 5 doses recommended by ACIP should be carefully considered (3).
An ongoing challenge in managing PEP in immunosuppressed persons remains our inability 
to predict which of these persons is likely to have a poor antibody response. While it was not 
surprising to see that the liver recipient had the most robust antibody response among the 3 
recipients, given that he was taking fewer immunosuppressive medications than the other 2 
recipients, the overwhelming superiority of his response seems out of proportion to 
differences in immunosuppressive medications. Indeed, the antibody response mounted by 
the liver recipient exceeds that reported for other liver transplant recipients at a similar point 
following completion of vaccination (36.8 IU/mL vs. 11.69 IU/mL in a liver transplant 
recipient aged 17 years) (7). These observations suggest that other intrinsic host factors 
might also play a role in how a person responds to PEP.
Another uncertainty in managing PEP for immunosuppressed persons is the duration over 
which they should demonstrate a target RVNA level. For example, the liver and heart 
recipients both had declining antibody titers as of the final serum sample that was evaluated; 
in contrast, the right kidney recipient had an increased antibody titer, despite not having 
recently received rabies vaccine or having had any changes in his immunosuppressive 
medication regimen. Whether this situation, particularly for the liver and heart recipients, 
necessitates ongoing serologic evaluation remains unclear.
While some data are available regarding PEP in persons with human immunodeficiency 
virus, additional investigations of PEP responses are urgently needed among other classes of 
immunosuppressed persons, such as transplant recipients (25, 26). From a laboratory 
perspective, evaluation of T- and B-cell responses and other markers of immune function 
after administration of rabies vaccine should be a priority area for further investigation (27, 
28). An international registry to systematically report experiences with PEP for 
immunosuppressed individuals could help clinicians and public health officials make 
evidence-based treatment recommendations (5). Finally, prospective studies that aim to 
enroll transplant recipients and measure immune responses to PEP should be conducted; the 
advantage of such an approach is that it will allow recruitment of a more homogenous study 
population focused on the transplant setting (6).
The survival of 3 previously unvaccinated recipients of solid organs from a donor with 
rabies is an unexpected and unprecedented situation. Although we do not know the exact 
circumstances that led to their survival, our data suggest for the first time that PEP can 
possibly enhance transplant safety in settings in which donors are retrospectively diagnosed 
with rabies.
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Antibody responses to rabies post-exposure prophylaxis (PEP) among 3 patients who 
received solid organs procured from a donor with rabies. The graph shows the concentration 
of rabies virus neutralizing antibodies (RVNAs) (Y-axis, logarithmic scale) at various time 
points after initiation of rabies PEP (X-axis) for 3 solid organ recipients who had received 
organs procured from a donor with rabies. The lower limit of detection for RVNAs by the 
laboratory assay we used is 0.04 IU/mL but, for simplicity, 0.05 IU/mL is indicated on this 
graph. The cutoff defined by the Advisory Committee on Immunization Practices for an 
acceptable antibody response to administration of rabies vaccine corresponds to an RVNA 
concentration of approximately 0.1 IU/mL; in contrast, the World Health Organization 
cutoff is 0.5 IU/mL.
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Table 1
Antibody responses to rabies post-exposure prophylaxis (PEP) and immunosuppressive medications used by 3 














Liver 18 0 <0.04 TAC (4–8 ng/mL)
18 3 0.1 TAC (4–8 ng/mL)
19 14 0.5 TAC (4–8 ng/mL)
19 28 2.2 TAC (4–8 ng/mL)
20 42 40.8 TAC (4–8 ng/mL)
20 62 36.8 TAC (4–8 ng/mL)
28 280 10.0 TAC (4–8 ng/mL)
Right kidney 18 0 <0.04 TAC (6–8 ng/mL) MPA (1.5–2.5 µg/mL)
19 14 0.4 TAC (6–8 ng/mL) MPA (1.5–2.5 µg/mL)
19 28 0.3 TAC (6–8 ng/mL) MPA (1.5–2.5 µg/mL)
20 39 0.3 TAC (6–8 ng/mL) MPA (1.5–2.5 µg/mL)
21 68 0.3 TAC (6–8 ng/mL) MPA (1.5–2.5 µg/mL)
28 279 0.5 TAC (6–8 ng/mL) MPA (1.5–2.5 µg/mL)
Heart 18 0 <0.04 TAC (10–12 ng/mL) Prednisone 2.5 mg/day
19 14 0.4 TAC (10–12 ng/mL) Prednisone 2.5 mg/day
20 49 0.3 TAC (10–12 ng/mL) Prednisone 2.5 mg/day
21 68 0.3 TAC (10–12 ng/mL) Prednisone 2.5 mg/day
36 533 <0.04 TAC (6–8 ng/mL) Sirolimus (4–8 ng/mL)
RVNA, rabies virus neutralizing antibody; TAC, tacrolimus; MPA, mycophenolic acid.
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